단계 미표기모집 중단 (진행 중)

A Survey of Lanadelumab in Participants With Hereditary Angioedema

연구 개요

This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.

스폰서
리드: 다케다
적응증
Hereditary Angioedema (HAE)
중재
Lanadelumab
목표 등록
155
시작일
2022-05-30
완료(예정)
2026-06-25

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.